Compound research hub

Tesamorelin: Research, Handling and Batch Documentation

Tesamorelin is a trans-3-hexenoyl GHRH(1-44) analogue, and the only growth-hormone-releasing peptide in this catalogue with a completed phase 3 programme behind an approved indication.

Part of Volta's growth hormone research peptides catalogue.

Identity and research status

Also referred to as: Egrifta, Egrifta SV, Egrifta WR, TH9507
Sequence: trans-3-hexenoyl-modified human GHRH(1-44) amide
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.86 g/mol
CAS Number: 218949-48-5
Length: 44 amino acids plus an N-terminal acyl group
Key Modification: trans-3-hexenoyl group at the N-terminus, blocking DPP-4 cleavage
Receptor Target: GHRH receptor on pituitary somatotrophs
Also Known As: TH9507, tesamorelin acetate
Regulatory Status: Approved for HIV-associated lipodystrophy in the United States
Appearance: White lyophilised powder
CAS number: 901758-09-6

Evidence level: FDA Approved (grade A)

Regulatory status: FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy

Evidence grades describe the published literature on the compound, not a property of the material Volta supplies, and are not a statement that any use is approved. See how these grades are assigned.

Mechanism, in brief

Tesamorelin is a stabilised analogue of human growth hormone releasing hormone, built on the full 44 residue sequence rather than the 29 residue fragment used by sermorelin, and carrying a trans-3-hexenoyl group attached at the N-terminus. That acyl group is the defining modification: it protects the vulnerable N-terminal region from dipeptidyl peptidase-4, which cleaves native GHRH near position 2 and destroys the determinant required for receptor activation.

N-terminal protection. A trans-3-hexenoyl group at the N-terminus blocks dipeptidyl peptidase-4 cleavage of the region required for receptor activation, which is what native GHRH lacks.
Receptor activation. Full agonism at the GHRH receptor on pituitary somatotrophs, signalling through Gs and cyclic AMP.
Growth hormone release and synthesis. Cyclic AMP both triggers release of the stored pool and stimulates synthesis, so the effect is not limited to depleting existing stores.
Feedback preserved. Somatostatin tone and IGF-1 negative feedback remain intact, keeping secretion pulsatile and self-limiting in a way exogenous growth hormone is not.
Preferential visceral lipolysis. Growth hormone acts preferentially on visceral adipose tissue, which is the basis for the compartment-selective fat reduction reported in the clinical programme.

The full research write-up, including the findings behind each claim and the model each came from, is on the Tesamorelin 10mg 10mg page.

Vial sizes available

Every size of Tesamorelin Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.

Tesamorelin 10mg 10mgBatch #: VPTS10100
In stock

Purity and batch documentation

Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.

SideChain Analytics reported 99.5% by HPLC-MS/MS on September 24, 2026.
Covers the Tesamorelin 10mg vial.
Read the certificate Verify on lab's website (Verify on SideChain Analytics's website, opens in a new tab)

the complete batch history dataset how each batch is tested laboratories that test peptides independently

Research on Tesamorelin

Concentrations used in the literature

the concentrations used in the published tesamorelin trials

Comparisons

Studied alongside other compounds

tesamorelin alongside ipamorelin in the literature

Class guide

the growth hormone secretagogue class guide

Handling and stability

Laboratory guides

Calculators

Regulatory context

United States: FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only.
Canada: Approved by Health Canada. Manufactured by Theratechnologies Inc. in Montreal.
United Kingdom: Not MHRA-approved.

Primary sources

Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs (2011). PMID 21668043
Stanley TL, Falutz J, Marsolais C, et al.. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases (2012). PMID 22495074
Mangili A, Falutz J, Mamputu JC, et al.. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One (2015). PMID 26457580
Ditta AM, Naeem RM, et al.. Efficacy and Safety of Tesamorelin in People Living With HIV With Lipodystrophy: A Systematic Review. Journal of the International Association of Providers of AIDS Care (2026). PMID 42538058
Badran AS, Helal A, et al.. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue. Obesity Research and Clinical Practice (2026). PMID 41545261
Dominikowski A, Rękoś Z, et al.. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Frontiers in Endocrinology (2026). PMID 42395176

More growth hormone research peptides

Tesamorelin sits in Volta's growth hormone research peptides catalogue, alongside the other compounds studied in this area. The whole range is on the full research catalogue, and the library of comparisons and guides is under peptide research.